Nutex Health Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nutex Health Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $875.26M | Mar 5, 2026 |
| FY2024 | Dec 31, 2024 | $257.62M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $69.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $53.72M | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $331.53M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $274.03M | Mar 3, 2023 |
| FY2020 | Dec 31, 2019 | $1.37M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $1.37M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $23.2K | Apr 17, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $23.2K | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Apr 17, 2018 |
| FY2015 | Dec 31, 2015 | $474.7K | Apr 14, 2016 |
| FY2014 | Dec 31, 2014 | $1.07M | Apr 15, 2015 |
| FY2014 | Dec 31, 2013 | $1.46M | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $1.59M | Apr 1, 2014 |
| FY2012 | Dec 31, 2011 | $1.78M | Jun 20, 2013 |
| FY2011 | Dec 31, 2010 | $874.8K | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $444.28M | Mar 5, 2026 |
| FY2024 | Dec 31, 2024 | $141.63M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $13.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $530.3K | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $179.28M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $157.61M | Mar 3, 2023 |
| FY2020 | Dec 31, 2019 | $536.0K | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $859.4K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($7.3K) | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 17, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2024 | $61.70M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($31.62M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($14.75M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $132.59M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $105.97M | Mar 3, 2023 |
| FY2020 | Dec 31, 2019 | ($7.12M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | ($950.1K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $582.1K | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | ($7.43M) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $275.63M | Mar 5, 2026 |
| FY2024 | Dec 31, 2024 | $114.21M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($26.14M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.78M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $170.26M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $153.17M | Mar 3, 2023 |
| FY2020 | Dec 31, 2019 | ($6.90M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | ($840.4K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($5.69M) | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | ($448.6K) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $285.9K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $557.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $768.1K | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $545.2K | May 14, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $248.13M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $23.15M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $1.26M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $50.61M | Nov 18, 2025 |
| FY2023 | Dec 31, 2021 | $173.43M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $86.67M | Mar 3, 2023 |
| FY2020 | Dec 31, 2019 | ($4.04M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | ($480.0K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($714.6K) | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | ($274.2K) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.30M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $9.50M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $14.63M | Nov 18, 2025 |
| FY2022 | Dec 31, 2021 | $36.93M | Mar 3, 2023 |
| FY2022 | Dec 31, 2020 | $61.19M | Mar 3, 2023 |
| FY2020 | Dec 31, 2019 | $84.0K | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 14, 2020 |
| FY2015 | Dec 31, 2015 | ($1.8K) | Apr 14, 2016 |
| FY2014 | Dec 31, 2014 | ($2.0K) | Apr 15, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $918.53M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $655.32M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $398.25M | Nov 18, 2025 |
| FY2023 | Dec 31, 2022 | $431.75M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $394.65M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $169.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.69M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $449.4K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.33M | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | $510.8K | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $495.09M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $466.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $319.14M | Nov 18, 2025 |
| FY2023 | Dec 31, 2022 | $311.42M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $203.07M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $1.30M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.83M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $1.95M | May 14, 2020 |
| FY2016 | Dec 31, 2016 | $6.38M | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | $6.08M | Apr 17, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $329.45M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $132.44M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $61.45M | Nov 18, 2025 |
| FY2023 | Dec 31, 2022 | $95.86M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $114.65M | Mar 3, 2023 |
| FY2020 | Dec 31, 2020 | ($1.13M) | Apr 5, 2021 |
| FY2020 | Dec 31, 2019 | $1.86M | Apr 5, 2021 |
| FY2020 | Dec 31, 2018 | ($1.50M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2017 | ($997.2K) | May 14, 2020 |
| FY2018 | Dec 31, 2016 | ($5.87M) | Apr 17, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.92M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $13.92M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $17.07M | Mar 5, 2026 |
| FY2023 | Dec 31, 2022 | $17.01M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.14M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.47M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 14, 2020 |
| FY2018 | Feb 14, 2017 | $338.1K | Apr 17, 2019 |
| FY2015 | Dec 31, 2015 | $6.71M | Apr 14, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($286.19M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($356.98M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($409.07M) | Nov 18, 2025 |
| FY2023 | Dec 31, 2022 | ($363.29M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $102.32M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($18.22M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($12.57M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | ($5.45M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($9.65M) | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | ($10.23M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.57M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $40.64M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $22.00M | Mar 5, 2026 |
| FY2025 | Dec 31, 2022 | $34.26M | Mar 5, 2026 |
| FY2022 | Dec 31, 2021 | $36.12M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $26.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.07M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $119.3K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $9.4K | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | $10.5K | Apr 17, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Apr 5, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $300.0K | May 14, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | Mar 5, 2026 |
| FY2024 | Dec 31, 2024 | 11 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (7) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 3, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Mar 5, 2026 |
| FY2024 | Dec 31, 2024 | 11 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (7) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 3, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.09M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 5.51M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 4.51M | Nov 18, 2025 |
| FY2024 | Dec 31, 2022 | 4.33M | Nov 18, 2025 |
| FY2024 | Dec 31, 2021 | 3.95M | Nov 18, 2025 |
| FY2021 | Dec 31, 2020 | 5.28M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 4.65M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | 777,108 | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 116.20M | Apr 17, 2019 |
| FY2017 | Dec 31, 2016 | 39.71M | Apr 17, 2018 |